Kolexia
Faroux Roger Gastro-entérologie
Faroux Roger
Gastro-entérologie
Centre Hospitalier Départemental Vendée
La Roche-sur-Yon, France
131 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Tumeurs du côlon Adénocarcinome Métastase tumorale Tumeurs du foie Tumeurs du rectum Carcinomes Tumeurs du pancréas Carcinome hépatocellulaire

Collaborateurs

Voir plus
Bouche Olivier
Bouche Olivier
Hôpital Robert-Debré Reims, Reims, France
Taieb Julien
Taieb Julien
Hôpital Européen Georges Pompidou, Paris, France
Francois Eric
Francois Eric
Centre Antoine Lacassagne, Nice, France
Bennouna-Louridi Jaafar
Bennouna-Louridi Jaafar
Hôpital Foch, Suresnes, France

Industries

Voir plus
Amgen
2 collaboration(s)
Dernière en 2019
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
IDEA: A Phase III Randomized Trial Investigating the Duration of Adjuvant Therapy(3 Versus 6 Months) With the Modified FOLFOX 6 or XELOX Regimens for Patients With Stage III Colon Cancer
Essai Clinique (GERCOR (Multidisciplinary Group in Oncology))   27 septembre 2023
Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial.
Therapeutic advances in medical oncology   26 décembre 2022
REMINET: A EUROPEAN, MULTICENTRE, PHASE II/III RANDOMISED DOUBLE-BLIND, PLACEBO CONTROLLED STUDY EVALUATING LANREOTIDE AS MAINTENANCE THERAPY IN PATIENTS WITH NON-RESECTABLE DUODENO-PANCREATIC NEUROENDOCRINE TUMOURS AFTER FIRST-LINE TREATMENT
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   21 décembre 2022
The Characteristics of Diverticular Disease in Caribbean Population: A Control Group Study.
Canadian journal of gastroenterology & hepatology   07 décembre 2022
LBA28 Prognostic effect of imaging and CEA follow-up in resected colorectal cancer (CRC): Final results and relapse free survival (RFS) - PRODIGE 13 a FFCD phase III trial
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
Aflibercept-LV5FU2 as first-line treatment of non-resectable metastatic colorectal cancers: Results of the FOLFA randomized phase II trial.
2022 ASCO Annual Meeting I   02 juin 2022
DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial.
JAMA oncology   08 avril 2022
Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab: Phase II, Multicentric Randomized Trial, Evaluating the Efficacy of Fluoropyrimidine-based Standard Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab
Essai Clinique (Unicancer)   07 janvier 2022
Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma: Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma
Essai Clinique (Unicancer)   03 janvier 2022
SURVEILLANCE: Follow-Up of Fully Resected Stage II or III Colorectal Cancer. Phase III Multicentric Prospective Randomised Study
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   06 décembre 2021